CN104510745A - Application of triterpenoid saponin compound in preparation of drugs for preventing or treating scar hyperplasia - Google Patents
Application of triterpenoid saponin compound in preparation of drugs for preventing or treating scar hyperplasia Download PDFInfo
- Publication number
- CN104510745A CN104510745A CN201410508244.0A CN201410508244A CN104510745A CN 104510745 A CN104510745 A CN 104510745A CN 201410508244 A CN201410508244 A CN 201410508244A CN 104510745 A CN104510745 A CN 104510745A
- Authority
- CN
- China
- Prior art keywords
- scar hyperplasia
- apply
- scar
- saponin compound
- pharmaceutically acceptable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Molecular Biology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Steroid Compounds (AREA)
Abstract
The invention discloses an application of a triterpenoid saponin compound having the structural formula represented by the formula I, a pharmaceutically acceptable salt, a hydrate or an ester thereof in preparation of drugs for preventing or treating scar hyperplasia. The drugs prepared by using the triterpenoid saponin compound or the pharmaceutically acceptable salt, the hydrate or the ester thereof can effectively inhibit formation and proliferation of scars, can be widely used in preparation of drugs for preventing or treating various scars caused by wounds, scorching burns, acne, coining and cosmetology surgeries and the like in clinic.
Description
Technical field
The invention belongs to biological technical field, be specifically related to a kind of triterpene saponin compound and prevent in preparation or treat the application in the medicine of scar hyperplasia.
Background technology
According to statistics, China is high cicatrix body constitution country, and cicatrix body constitution crowd accounts for more than 85%, and cicatrix crowd accounts for more than 90%, promotes that the pharmaceutical market of wound healing cicatrization increases year by year.Cicatrization makes tissue injury be able to healing, is a kind of protective response that body resists wound.But, the reparation of cicatrix form is a kind of compensatory reparation after all, it can not recover the original form of damaged tissue completely, structure and fuction, especially when cicatrization occurs abnormal, often directly or indirectly cause biological organs or organize morphosis abnormal (deformity) in various degree or (with) dysfunction.
Scar hyperplasia is the common a kind of disease of surgery, and its treatment is orthopedic a great problem always.Medicine in recent years for scar treatment mainly contains steroid hormone class, polypeptide growth factor class and Chinese medicine class medicine, and Patients Treated with Steroid exists injection pain, the untoward reaction such as injection site atrophoderma, depigmentation, polypeptide growth factor is expensive and curative effect is very limited.Herba Centellae is the dry herb of samphire Herba Centellae Centella asiatica (L.) Urb., is distributed widely in China south China, North China, Central-South and southwest.Record according to Shennong's Herbal, its property bitter, acrid, cold, have clearing away heat-damp and promoting diuresis, effect of removing toxic substances, detumescence.Among the people being usually used in treats jaundice due to damp-heat, heatstroke diarrhoea, sand Stranguria stranguria with blood, carbuncle sore tumefacting virus, injury from falling down etc., its external and existing more than 2,000 years history of curing the disease for oral administration.Herba Centellae total glycosides is the effective site obtained through extraction and isolation from the herb of Umbelliferae Herba Centellae Centella asiatica (L.) Urban, have and suppress the effect of cicatrix hyper-proliferative, be widely used in the various wound for the treatment of clinically, burn wound, the cicatrix that acne and plastic and aesthetic surgery etc. cause.
Summary of the invention
Technical problem to be solved by this invention is for lacking the present situation that effectively can suppress the medicine of scar hyperplasia at present clinically, provides a kind of triterpene saponin compound, its pharmaceutically acceptable salt, hydrate or ester prevent in preparation or treat the application in the medicine of scar hyperplasia.
For solving the problems of the technologies described above, one of technical scheme that the present invention takes for: the triterpene saponin compound of a kind of structural formula as shown in formula I, its pharmaceutically acceptable salt, hydrate or ester preparation prevention or treatment scar hyperplasia medicine in application,
The preparation method of the triterpene saponin compound of structural formula of the present invention as shown in formula I, its pharmaceutically acceptable salt, hydrate or ester is this area customary preparation methods, preferably for business buys gained.Its pharmaceutically acceptable salt wherein said is the salt of this area routine, is preferably choline salt, glucose amine salt or tromethane salt.
The triterpene saponin compound of structural formula of the present invention as shown in formula I, its pharmaceutically acceptable salt, hydrate or ester may be used for pharmaceutical compositions, in this pharmaceutical composition described, the mass percentage content of the derivant of triterpene saponin compound or this compound is 0.01 ~ 99.99%, and the mass percentage content of pharmaceutical carrier is 0.01 ~ 99.99%.
Described pharmaceutical composition at least comprises a kind of active component: i.e. the triterpene saponin compound of structural formula as shown in formula I, its pharmaceutically acceptable salt, hydrate or ester and a kind of pharmaceutical carrier.In this pharmaceutical composition, the triterpene saponin compound of structural formula as shown in formula I, its pharmaceutically acceptable salt, hydrate or ester can as active component separately or together with other compounds.Described " active component " refers to the function with prevention or treatment scar hyperplasia.Described pharmaceutical carrier comprises pharmaceutically acceptable excipient, filler, diluent etc.
Triterpene saponin compound of the present invention, its pharmaceutically acceptable salt, hydrate or ester can use as active component separately or use together with active component with the medication combined of the anti-scar hyperplasia of routine, the medicine of preparation prevention or treatment scar hyperplasia.Conventional scar hyperplasia medicine of the present invention is the medicine with scar hyperplasia function existed in prior art." active component " of the present invention refers to the compound with prevention or treatment scar hyperplasia function.Wherein said pharmaceutical carrier is the pharmaceutical carrier of this area routine, preferably comprises pharmaceutically acceptable excipient, filler, diluent etc." prevention " of the present invention, refers under the existence of possible scar hyperplasia factor, prevents or reduce the generation of scar hyperplasia after using medicine." treatment " of the present invention, refers to the degree utilizing medicine lessen scar formation hypertrophy, or healing scar hyperplasia makes it normalization, or slows down the process of scar hyperplasia.
Application of the present invention is preferably: utilize triterpene saponin compound of the present invention, its pharmaceutically acceptable salt, hydrate or ester to prevent or treat the medication combined of scar hyperplasia preparing as active component the application preventing or treat in the medicine of scar hyperplasia with conventional as single-activity composition or this compound.
The dosage form of medicine of the present invention is not particularly limited, and described pharmaceutical dosage form is preferably liniment, gel, unguentum, cataplasma, cutaneous permeable agent or biological membrane.For gel wherein, medicine of the present invention, when applying, first carries out smearing treatment, then coordinates other method to treat.
On the basis meeting this area general knowledge, above-mentioned each optimum condition, can combination in any, obtains the preferred embodiments of the invention.
Agents useful for same of the present invention and raw material are all commercially.
Positive progressive effect of the present invention is: the invention provides the application in the medicine of preparation treatment scar hyperplasia of the triterpene saponin compound of a kind of structural formula as shown in formula I, its pharmaceutically acceptable salt, hydrate or ester, utilize the derivant containing triterpene saponin compound of the present invention or this compound as the Drug therapy scar hyperplasia of active component, the curative effect being obviously better than other drug significantly can be obtained.
Accompanying drawing explanation
Fig. 1 is the result of variations figure that compound and Herba Centellae total glycosides act on OD value after people's fibroblasts from hyperplastic scar.Wherein Fig. 1 (A) is for adding the testing result figure of drug effect after 16 hours; Fig. 1 (B) is for adding the testing result figure of drug effect after 32 hours.
Detailed description of the invention
Mode below by embodiment further illustrates the present invention, but does not therefore limit the present invention among described scope of embodiments.The experimental technique of unreceipted actual conditions in the following example, conventionally and condition, or selects according to catalogue.
Embodiment 1 prepares triterpene saponin compound
1, triterpene saponin compound monomer component is extracted
Herba Centellae total glycosides is bought from Guangxi Chang Zhou natural product development corporation, Ltd.; Preparative liquid chromatograph: Shimadzu chromatograph (pump: LC-8A, detector: SPD-M 10A) Shimadzu, Japan; Column chromatography silica gel: 200 ~ 300 orders, buys from Industrial Co., Ltd. of upper marine nation; Semi-preparative liquid chromatography post: Shimadzu PRC-ODS C18 (20mm × 250mm, 15 μm) buys from Shimadzu, Japan.
Get Chinese medicine extract Herba Centellae total glycosides 150g, through silica gel column chromatography (400g, chloroform: methanol: water=10:2:0.2,10:4:0.4,10:5:0.6,10:6:1 gradient elution, each gradient 6L), obtain 12 eluting positions (Fr.1 ~ 12).Wherein Fr.6 is through preparative liquid chromatography (prep.HPLC) (mobile phase: methanol/water=70:30; Flow velocity: 6.0ml/min; Determined wavelength: 204nm; Column temperature: 30 DEG C) be separated obtain 5 eluting positions (Fr.6-1 ~ 6-5); Fr.6-2 is through prep.HPLC (acetonitrile/water=30:70,6ml/min, 204nm, 30 DEG C) be separated obtain 4 eluting positions (Fr.6-2a ~ 6-2d), Fr.6-2a is again through prep.HPLC (acetonitrile/water=24:76,6ml/min, 204nm, 30 DEG C), be separated and obtain compound (t
r: 44min) 43mg, yield 0.029%.
Also (document [1] is the extraction and isolation step that can refer in document [1]: Matsuda H, MorikawaT, Ueda H, et al.Medicinal foodstuffs.XX VII .Saponin constituents of Gotu Kola (2): structures of new ursane-and oleanane-type triterpene oligoglycosides, centellasaponins B, C, and D, from Centella asiatica cultivated in Sri Lanka [J] .Chem Pharm Bull, 2001, 49 (10): 1368-1371.).
2, the structure of deterministic compound
Gained compound is white powder; Through MS-ESI,
13c-NMR,
1h-NMR measures, and the spectral data obtaining compound is as follows: ESI-MS (m/z): 851.50 [M+Na]
+(positive), 863.53 [M+Cl]
-(negative); Testing result is specifically shown in Table 1.
Also can refer to structure ([1] Matsuda H of document [1] deterministic compound, Morikawa T, Ueda H, et al.Medicinal foodstuffs.XX VII .Saponin constituents of Gotu Kola (2): structures of new ursane-and oleanane-type triterpeneoligoglycosides, centellasaponins B, C, and D, from Centella asiatica cultivatedin Sri Lanka [J] .Chem Pharm Bull, 2001,49 (10): 1368-1371.).
Table 1 compound
13c-NMR and
1h-NMR data (100 and 400MHz, C
5d
5n)
Through qualification, the molecular formula of gained compound is: C
42h
68o
16, its structural formula is as shown in formula I:
The anti-scar hyperplasia determination of activity of embodiment 2 triterpene saponin compound
Cell strain: HSF cell strain (strain of people's fibroblasts from hyperplastic scar), buys from CellResearch company of Singapore; DMEM is high, and sugared culture fluid is bought from Gibco company of the U.S.; Hyclone is bought from Gibco company of the U.S.; Dual anti-(penicillin, streptomycin) is bought from Gibco company of the U.S.; Pancreatin is bought from Gibco company of the U.S.; Tetramethyl azo azoles salt (MTT) is bought from SIGMA company of the U.S.; Isobutanol, sodium lauryl sulphate (SDS) is bought from Chemical Reagent Co., Ltd., Sinopharm Group; Three lysates: 10%SDS, 5% isobutanol, 0.012mol/L HCL, distilled water dissolves preparation; LDH test kit is bought from Japanese wako Products; Automatic CO
2incubator is bought from FormaScientific company of the U.S.; Thermo Multiskan MK3 microplate reader is bought from THERMO FISHER company of the U.S.; Inverted microscope is bought from Japanese Olympus company; HITACHI 7060 automatic clinical chemistry analyzer is bought from Japanese HITACHI company.
By MTT colorimetric determination triterpene saponin compound to the inhibitory action of scar fibroblast proliferation, measure triterpene saponin compound to fibroblast with or without cytotoxicity by lactic acid dehydrogenase (LDH) method.Specific experiment method comprises the following steps:
(1) sample preparation: embodiment 1 prepares gained triterpene saponin compound monomer with containing the dissolving of 1%DMSO culture medium solution, and is diluted to 0.01mg/ml, the sample of 0.05mg/ml, 0.1mg/ml, 0.5mg/ml and 1.0mg/ml concentration.
(2) fibroblasts from hypertrophic scars morphological observation: experiment choose be in exponential phase 4th ~ 6 generation fibroblast.Use 0.25% trypsinization, serum neutralizes, and blows and beats into cell suspension.Transfer in centrifuge tube by gained cell suspension, 1500r/min 5min is centrifugal, abandons supernatant.In centrifuge tube, add 4ml DMEM repeatedly blow and beat, and count under the microscope.96 orifice plates are seeded to, every hole 100 μ l with the concentration of 10000 cell/ml; 5 holes are stayed only to add culture fluid as blank well.CO
224h (5%CO is cultivated in constant incubator
2, 37 DEG C).Sucking-off stock solution after cell attachment, sets up matched group and experimental group, and each sample standard deviation establishes 5 multiple holes.Matched group changes liquid, every Kong Jiahan 1%DMSO hydroponics base 100 μ l; Experimental group adds each 100 μ l of sample solution containing variable concentrations respectively, is divided into 16h group and 32h group, at CO
2continue in constant incubator to cultivate.Make a video recording under inverted microscope in two time periods of 16h and 32h respectively.
(3) MTT colorimetry observation fibroblasts from hypertrophic scars vigor: respectively after cultivation 16h and 32h shooting, the MTT solution 20 μ l that every hole adds 5mg/ml continues to cultivate 4h.Every hole adds 100 μ l tri-lysates, puts 37 DEG C of calorstats and places (lucifuge) cultivation of spending the night, with blank well zeroing, enzyme linked immunological spectroscope wavelength is detected as the absorption value (OD value) at 570nm place.
(4) lactic acid dehydrogenase (LDH) determination of activity: get experimental group and matched group supernatant when the drug effect 16h added and 32h respectively, utilize LDH test kit (Japanese wako Products) and automatic biochemistry analyzer to detect LDH numerical value in cell, specific experiment method refers to the description of LDH test kit.
(5) statistical method: measurement data is used
describe, paired data t checks, and many group mean one factor analysis of variance, inspection level has significant difference with P<0.05, and P<0.01 has significant differences.
Experimental result:
(1) fibroblasts from hypertrophic scars morphological change observed by inverted microscope:
Under mirror, visible 1%DMSO cellular control unit profile is long and narrow, and karyon is fusiformis, trend reaches unanimity, many in arranged in parallel and have certain radian.There are circle or oval forming core in cell central authorities, and part cell is protruding 2 ~ 3 projections different in size as seen, are fibroblast.Along with the increase of incubation time, cell quantity increases, and intercellular substance narrows, in streak distribution.
Compared with 1%DMSO matched group, triterpene saponin compound monomer processed group visible cell after concentration reaches 0.5mg/ml shortens, quantity reduces, intercellular substance increases, contact with adjacent cells and reduce, display triterpene saponin compound has certain concentration dependent to fibroblastic inhibitory action.
(2) triterpene saponin compound is on the impact (mtt assay detection) of scar fibroblast proliferation
Observation embodiment 1 prepares the impact that gained triterpene saponin compound monomer is bred scar fibroblast, with the change-detection result of absorbance under 570nm (OD value) as shown in table 2 and Fig. 1, wherein Fig. 1 (A) is for adding the testing result figure of drug effect after 16 hours, and Fig. 1 (B) is for adding the testing result figure of drug effect after 32 hours.
Table 2 compound and Herba Centellae total glycosides act on the change of OD value after people's fibroblasts from hyperplastic scar
Compared with matched group, * P<0.01; Compared with total glycosides,
#p<0.05.
According to gained OD value result of variations, embodiment 1 is prepared triterpene saponin compound monomer shown in gained formula I and is had significant inhibitory action to fibroblasts from hypertrophic scars hypertrophy.
(3) triterpene saponin compound is to fibroblastic toxic action (LDH method)
Triterpene saponin compound monomer and the impact of Herba Centellae total glycosides on fibroblasts from hypertrophic scars LDH activity the results are shown in Table 3.Measuring the content of 1%DMSO matched group LDH, is 35 ~ 40U/L, using its fluctuation range as the normal range detected.Through comparison, the concentration of triterpene saponin compound monomer and Herba Centellae total glycosides is when 0.01 ~ 1.0mg/ml, and in fibroblast, the content of LDH is all in normal range, demonstrates triterpene saponin compound monomer and Herba Centellae total glycosides to fibroblast all free of toxic effects.
Table 3 triterpene saponin compound and Herba Centellae total glycosides are on the impact of fibroblasts from hypertrophic scars LDH activity
According to the display of the data obtained result, compound shown in formula I has very strong inhibitory action to fibroblasts from hypertrophic scars hypertrophy.
4, triterpene saponin compound monomer is on the impact of rabbit ear hypertrophic cicatrix
Laboratory animal: new zealand white rabbit 8 (buying from Jia Gan bio tech ltd, Shanghai), body weight (2.5 ± 0.5) kg, the rabbit ear perfects.
(1) making of animal model: select healthy adult new zealand white rabbit 8, sub-cage rearing 1 week.Auricular vein anesthesia is done with 3% pentobarbital sodium (30mg/kg), under strict aseptic technique technology, avoid visible vessels at rabbit ear veutro along major axis, wound surface interval more than lcm, do lcm × lcm size wound surface, remove rabbit ear full thickness skin and perichondrium, edge of wound flatiron burns, and every rabbit ear does 6 identical wound surface, totally 96 wound surface, postoperative wound surface exposes, and treats wound surface self-heal.After epithelization, rabbit is divided into two groups at random, often organize 4, the embodiment 1 that experimental group, matched group give 50mg/kg respectively prepares gained triterpene saponin compound monomer and each 10ml gavage of normal saline.Every day 1 time, continuous 6 times.
(2) specimen collection: after last gavage 1 day (postoperative 28 days), does auricular vein anesthesia with 3% pentobarbital sodium (30mg/kg), and often group is random puts to death 2 rabbits, cuts specimen.Residue rabbit continues to feed, and when postoperative 56 days, puts to death equally and often organizes last 2 rabbits, cut scar tissue specimen under anesthesia.The specimen doing HE dyeing is fixed with 4% neutral formalin, then paraffin embedding.Measure scar hyperplasia situation, light Microscopic observation.
(3) scar hyperplasia situation is observed: hinder rear 19 ~ 21 days (during epithelization), within postoperative 28 days and 56 days, observe and record scar hyperplasia situation.Scar tissue Scar height is more than or equal to 2mm, is hypertrophic cicatrix when hardness is similar to rabbit ear cartilage.
(4) statistical method: adopt SPSS12.0 statistical analysis software to carry out variance analysis and q inspection to measurement data.
Experimental result:
(1) cicatrization situation: can contact lump during epithelization, this lump is constantly higher than surface, and pale red, hypertrophy scope is no more than original edge, and within about 28 ~ 32 days, hypertrophy is to summit.Experimental group rabbit ear cicatrix quality is smooth compared with matched group softness.
(2) scar hyperplasia index (HI) contrasts situation (see table 4): measure scar hyperplasia index (Hypertrophic Index), relative hypertrophy thickness is measured with micrometer under microscope, the height (scar height) of setting cicatrix is SH, normal skin height (dermis height) is DH, then HI=SH/DH.
Table 4 scar hyperplasia index
Compare with matched group: * p<0.01
(3) tissue slice is observed
Negative control group: the skin corium showing scar tissue on negative control group laboratory animal skin under mirror obviously thickens, for 4 ~ 5 times of periphery normal dermal layer thickness, reach 2 ~ 2.5mm, mainly to embark on journey in a large number fibrocyte proliferation, collagen fiber are how and fine and close thick, fall into disarray, visible swirling structure and collagen tuberosity, there is a small amount of inflammatory cell therebetween, the hypertrophic scar tissue of structure proximate people.
Experimental group: under mirror, check result display is compared with skin corium normal thickness 0.5mm, and utilize the dermis thickness of the test group of animals of triterpene saponin compound monomer of the present invention process to be about 1mm, its thickness is 2 times of normal dermal layer thickness; And the fibroblast quantity of test group of animals skin obviously reduces, arrangement comparison rule, in horizontal direction.As described above, the skin corium thickness without the negative control group laboratory animal of triterpene saponin compound process significantly increases, and reaches 2 ~ 2.5mm, and its thickness is 4 ~ 5 times of normal dermal layer, the reduction amplitude highly significant of skin corium thickness.Above-mentioned experimental result sufficient proof, the scar hyperplasia tool of triterpene saponin compound of the present invention to laboratory animal has significant therapeutic effect.
Should be understood that those skilled in the art can make various changes or modifications the present invention after having read foregoing of the present invention, these equivalent form of values fall within the application's appended claims limited range equally.
Claims (10)
1. the triterpene saponin compound of structural formula as shown in formula I, its pharmaceutically acceptable salt, hydrate or ester prevent in preparation or treat the application in the medicine of scar hyperplasia,
2. apply as claimed in claim 1, it is characterized in that, described scar hyperplasia is the scar hyperplasia caused by fibroblast proliferation.
3. apply as claimed in claim 1, it is characterized in that, described scar hyperplasia is the scar hyperplasia caused by wound.
4. apply as claimed in claim 1, it is characterized in that, described scar hyperplasia is by burning the scar hyperplasia of hindering and causing.
5. apply as claimed in claim 1, it is characterized in that, described scar hyperplasia is the scar hyperplasia caused by acne.
6. apply as claimed in claim 1, it is characterized in that, described scar hyperplasia is the scar hyperplasia caused by plastic and aesthetic surgery.
7. apply as claimed in claim 1, it is characterized in that, it is active component and at least one pharmaceutical carrier that the medicine of described prevention or treatment scar hyperplasia comprises the triterpene saponin compound of structural formula as claimed in claim 1 as shown in formula I, its pharmaceutically acceptable salt, hydrate or ester.
8. apply as claimed in claim 7, it is characterized in that, described pharmaceutical carrier is pharmaceutically acceptable excipient, one or more in filler and diluent.
9. apply as claimed in claim 7, it is characterized in that, the dosage form of the medicine of described prevention or treatment scar hyperplasia is liniment, gel, unguentum, cutaneous permeable agent or biological membrane.
10. apply as claimed in claim 1, it is characterized in that, the triterpene saponin compound of structural formula as shown in formula I, its pharmaceutically acceptable salt, hydrate or ester prevent or treat the medication combined of scar hyperplasia preparing as active component the application preventing or treat in the medicine of scar hyperplasia with conventional as single-activity composition or this compound as claimed in claim 1.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410508244.0A CN104510745A (en) | 2013-09-30 | 2014-09-28 | Application of triterpenoid saponin compound in preparation of drugs for preventing or treating scar hyperplasia |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310461100X | 2013-09-30 | ||
| CN201310461100 | 2013-09-30 | ||
| CN201410508244.0A CN104510745A (en) | 2013-09-30 | 2014-09-28 | Application of triterpenoid saponin compound in preparation of drugs for preventing or treating scar hyperplasia |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN104510745A true CN104510745A (en) | 2015-04-15 |
Family
ID=52786984
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201410508244.0A Pending CN104510745A (en) | 2013-09-30 | 2014-09-28 | Application of triterpenoid saponin compound in preparation of drugs for preventing or treating scar hyperplasia |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN104510745A (en) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102349924A (en) * | 2011-08-16 | 2012-02-15 | 上海师范大学 | Centella asiatica triterpenic acid single-glucopyranoside composition, its preparation method, its quantitative analysis method and its application |
| CN102367263A (en) * | 2011-11-11 | 2012-03-07 | 上海师范大学 | Method for separating and purifying Centella asiatica triterpene acid monoglucoside |
-
2014
- 2014-09-28 CN CN201410508244.0A patent/CN104510745A/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102349924A (en) * | 2011-08-16 | 2012-02-15 | 上海师范大学 | Centella asiatica triterpenic acid single-glucopyranoside composition, its preparation method, its quantitative analysis method and its application |
| CN102367263A (en) * | 2011-11-11 | 2012-03-07 | 上海师范大学 | Method for separating and purifying Centella asiatica triterpene acid monoglucoside |
Non-Patent Citations (5)
| Title |
|---|
| HISASHI MATSUDA等: "Medicinal Foodstuffs. XXVII.1) Saponin Constituents of Gotu Kola (2): Structures of New Ursane- and Oleanane-Type Triterpene Oligoglycosides, Centellasaponins B, C, and D, from Centella asiatica Cultivated in Sri Lanka", 《CHEM. PHARM. BULL.》 * |
| JIE SONG等: "Madecassoside Induces Apoptosis of Keloid Fibroblasts Via a Mitochondrial-Dependent Pathway", 《DRUG DEVELOPMENT RESEARCH》 * |
| JIE SONG等: "Madecassoside suppresses migration of fibroblasts from keloids: involvement of p38 kinase and PI3K signaling pathways", 《BURNS》 * |
| 吴芳等: "积雪草三萜类成分促进创面愈合的研究进展", 《中国民族民间医药》 * |
| 陈军等: "积雪草酸及其衍生物的生物活性研究概况", 《中草药》 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Scheffler et al. | Olea europaea leaf extract exerts L-type Ca2+ channel antagonistic effects | |
| Chard et al. | Capsaicin-induced neurotoxicity in cultured dorsal root ganglion neurons: involvement of calcium-activated proteases | |
| CN100464756C (en) | Application of fucoidan in the preparation of medicine and health-care products for preventing and treating neurodegenerative diseases | |
| CN103327992A (en) | Pharmaceutical composition for preventing or treating inflammatory diseases comprising trachelospermi caulis extract and paeonia suffruticosa andrews extract, and method for preparing the same | |
| KR101888779B1 (en) | Use of isoquinoline alkaloid derivative for preparing drug capable of promoting ampk activity | |
| Pahlavan et al. | Effects of hawthorn (Crataegus pentagyna) leaf extract on electrophysiologic properties of cardiomyocytes derived from human cardiac arrhythmia‐specific induced pluripotent stem cells | |
| Gerhardt et al. | Boldine: a potential new antiproliferative drug against glioma cell lines | |
| CN103435580A (en) | Lingzhiol A and application of lingzhiol A in drug production and foods | |
| Markowicz-Piasecka et al. | Metformin and its sulphonamide derivative simultaneously potentiateanti-cholinesterase activity of donepezil and inhibit beta-amyloid aggregation | |
| EP3339285B1 (en) | A compound isolated from isodon forrestii var. forrestii and preparation method and applications thereof | |
| Deng et al. | Synthesis and discovery of new compounds bearing coumarin scaffold for the treatment of pulmonary fibrosis | |
| US20110053872A1 (en) | Pharmaceutical Composition For Preventing And Treating Diabetic Nephropathy And The Preparation Method Thereof | |
| CN100515431C (en) | Application of active material of sea cucumber as medication or health products | |
| Liu et al. | Inhibition of GluN2B pathway is involved in the neuroprotective effect of silibinin on streptozotocin-induced Alzheimer's disease models | |
| CN102552233A (en) | Application of methyl 3, 4-dihydroxybenzoate in preparation of medicaments for preventing and treating nerve degenerative diseases | |
| Zhou et al. | Inhibitory effects of amines from Citrus reticulata on bleomycin-induced pulmonary fibrosis in rats | |
| CN104510745A (en) | Application of triterpenoid saponin compound in preparation of drugs for preventing or treating scar hyperplasia | |
| CN110776409B (en) | Method for extracting pterocarpus indicus and application of extract in antitumor drugs | |
| Li et al. | Baicalin− 2-ethoxyethyl ester alleviates renal fibrosis by inhibiting PI3K/AKT/NF-κB signaling pathway | |
| CN101104612A (en) | Flavonol beta-secretase inhibitor in ginkgo leaf standard extract, extracting method and use thereof | |
| Sun et al. | First ayurvedic approach towards green drugs: anti cervical cancer-cell properties of Clerodendrum viscosum root extract | |
| CN108310125B (en) | Application of Qianliexin in antithrombotic drugs | |
| CN101239057A (en) | Use of salvianolic acid B and its salt in treating parkinson's disease | |
| Mohesh et al. | Effect of methanolic extract of Dendrophthoe falcata leaves on acute hyperglycemic adult zebrafish | |
| Ilyas et al. | Effect of Zanthoxylum acanthopodium methanol extract on CDK4 expression to cervical cancer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20150415 |
|
| RJ01 | Rejection of invention patent application after publication |